Electra Therapeutics

What Electra Therapeutics does

Electra Therapeutics is a clinical-stage biotechnology company developing SIRP-targeted antibody therapies for immunological diseases and cancer. Founded in 2018 under parent company Star Therapeutics and spun out as an independent entity in February 2022, the company is headquartered in South San Francisco, California, and operates with a lean team of 11–50 employees. Its lead investigational therapy, ipsoprubart (ELA026), is a first-in-class human monoclonal antibody that targets SIRP-alpha, -beta1, and -gamma on myeloid cells and T lymphocytes to selectively deplete pathological immune cells driving hyperinflammatory conditions and hematologic malignancies, without disrupting the CD47/SIRP-alpha "don't eat me" checkpoint.

The clinical pipeline is anchored by the SURPASS Phase 2/3 pivotal trial (NCT05416307) evaluating ipsoprubart in treatment-naïve adult and pediatric patients with secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory condition with no approved therapies and approximately 50% mortality at two months in malignancy-associated HLH. Phase 1b results demonstrated 100% overall survival at 8 weeks, 100% overall response rate by week 4, 100% hospital discharge, and 92% survival at Day 60 in mHLH patients—versus roughly 40–50% benchmarks for available off-label regimens. A Phase 1 study in relapsed/refractory T cell malignancies was initiated in May 2026, and a second SIRP-targeted program, ELA822, is advancing into the clinic for immunology and inflammation applications. ELA026 has received FDA Breakthrough Therapy Designation, EMA PRIME designation, and EMA Orphan Drug Designation—the first such designations granted for any sHLH therapy.

Electra Therapeutics is pre-commercial and does not yet generate product revenue. Its business model is centered on advancing clinical-stage assets toward regulatory approval and eventual commercialization, with potential future revenue streams from product sales, licensing fees, and milestone payments from pharmaceutical partners. The company has raised approximately $267 million in equity capital across the $84M Series B (February 2022) and $183M Series C (October 2025), with prior funding from parent Star Therapeutics; the Series C was co-led by EQT Life Sciences and Nextech Invest and included strategic investor Sanofi. Commercialization will ultimately rely on specialty pharmacy and hospital procurement channels typical of ultra-rare disease therapeutics, distributed through a small set of academic and tertiary hematology/oncology centers.

Name

Electra Therapeutics

Legal name

Electra Therapeutics, Inc.

Website

https://electra-therapeutics.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Electra Therapeutics is a clinical-stage biotechnology company developing first-in-class SIRP-targeted antibody therapies, with lead candidate ipsoprubart (ELA026) in pivotal development for secondary hemophagocytic lymphohistiocytosis and relapsed/refractory T cell malignancies.

Ownership category

akta.pro rank

Product category

Biopharmaceutical antibody therapy

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAAAO

Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIACAJ

Transplant & Immunosuppression Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Antibody therapy development
• Immunological disease treatments
• Oncology biologics
• Clinical stage biotechnology
• Monoclonal antibody pipeline

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biopharmaceutical Product Revenue (Future): As a pre-commercial, late-stage clinical biotech, Electra Therapeutics does not yet generate product revenue. Its value is derived from advancing clinical-stage drug candidates toward regulatory approval and commercialization. Potential revenue streams include product sales upon FDA/EMA approval, licensing fees, and milestone payments from pharmaceutical partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Electra Therapeutics is a clinical-stage biotechnology company developing a portfolio of Signal Regulatory Protein (SIRP)-targeted monoclonal antibody therapies. Its lead product candidate, Ipsoprubart (ELA026), is a first-in-class antibody targeting SIRP-alpha, -beta1, and -gamma to selectively deplete pathological myeloid cells and T lymphocytes driving hyperinflammatory conditions and hematologic malignancies, with the lead indication being secondary hemophagocytic lymphohistiocytosis (sHLH). A second program, ELA822, targets activated T lymphocytes for immunology and inflammation applications.

Product overview

Electra Therapeutics is a clinical stage biotechnology company developing a portfolio of SIRP (Signal Regulatory Protein)-targeted antibody therapies. The company's lead product is Ipsoprubart (ELA026), a first-in-class monoclonal antibody that selectively depletes pathological myeloid cells and T lymphocytes. Ipsoprubart is the primary candidate in pivotal development for secondary hemophagocytic lymphohistiocytosis (sHLH) and being expanded into T cell malignancies. The company is also advancing ELA822, a second SIRP-targeted program designed to selectively deplete activated T lymphocytes for immunology and inflammation applications. The pipeline includes preclinical programs in immunology and immuno-oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• Ipsoprubart (ELA026) First-in-class monoclonal antibody targeting signal regulatory proteins (SIRP)-alpha, -beta1, and -gamma on immune cells to selectively deplete pathological myeloid cells and T lymphocytes. Currently in pivotal development for secondary hemophagocytic lymphohistiocytosis (sHLH) and being evaluated in T cell malignancies.
• ELA822 Second SIRP-targeted antibody program designed to selectively deplete activated T lymphocytes, with broad potential applications across immunology and inflammation (I&I). Currently advancing toward clinical development.
• SURPASS Phase 2/3 Pivotal Clinical Trial (NCT05416307) Phase 2/3 open-label, single-arm registrational study evaluating Ipsoprubart (ELA026) in treatment-naïve adult and pediatric patients with secondary hemophagocytic lymphohistiocytosis (sHLH), with two cohorts (malignancy-associated HLH and non-malignancy triggered HLH). Primary endpoint is 8-week overall survival.
• ELA026 Phase 1 Study in T Cell Malignancies (NCT07465835) Open-label Phase 1 study evaluating Ipsoprubart (ELA026) in adult patients with relapsed or refractory T cell malignancies, with up to 24 patients in Part 1 to identify dosing regimens and expansion cohorts in Part 2, with up to six cycles (24 weeks) of monotherapy treatment.

Quantifiable outcome

• 100% overall survival at 8 weeks in malignancy-associated HLH (mHLH) patients (Phase 1b), vs. ~50% with available therapies
• +5 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered flagship, core and minor.

• Star Therapeutics (Parent Company)flagshipStrategic or Co-development Partner · 1 January 2018Star Therapeutics is the parent company and innovation engine that spun out Electra Therapeutics in February 2022. Star was founded in 2018 and has raised over $100 million from investors including Westlake Village BioPartners, OrbiMed, Redmile Group, Cormorant, RA Capital, Cowen Healthcare Investments, and New Leaf Venture Partners. Electra was initially funded through Star's investment. Adam Rosenthal, PhD, co-founder and former CEO of Electra, serves as CEO of Star. Both companies are co-located and share scientific talent and certain corporate departments, while maintaining separate financing and business development strategies.
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerThe University of Texas MD Anderson Cancer Center is a key clinical trial site and collaborator for the SURPASS pivotal study and Phase 1 studies. Dr. Swaminathan Iyer (Department of Lymphoma/Myeloma) and Dr. Abhishek Maiti (Department of Leukemia) are key investigators. MD Anderson sees thousands of patients annually, providing access to sHLH and lymphoma patients for clinical enrollment.
• Vanderbilt University Medical Center / MedStar Georgetown University / EpidStrategiesminorStrategic or Co-development PartnerClinical investigators from Vanderbilt University Medical Center (Dr. Daniel Hausrath) and MedStar Georgetown University (Dr. Catherine Broome) collaborated with Electra on a company-sponsored natural history study characterizing disease burden in sHLH patients. The study analyzed 232 adult patients over 16 years through electronic health record queries. EpidStrategies provided analytical support.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Apellis Pharmaceuticals: Commercial-stage biotech developing therapeutics (pegcetacoplan) for rare hematology/ophthalmology indications via engineered biologics. Comparable as a recently-launched, single-mechanism rare-disease biotech with premium pricing power.
• AB2 Bio (Tadekinig alfa program): Smaller biotech developing IL-18BP (tadekinig alfa) for HLH/MAS and other inflammatory diseases. The most direct emerging-play peer given overlapping indication (HLH family) and cytokine-directed mechanism targeting hyperinflammatory pathology similar to Electra's sHLH focus.

Direct peers

• Trillium Therapeutics (Pfizer): Developed SIRPα-Fc fusion proteins (TTI-621, TTI-622) for hematologic malignancies and was acquired by Pfizer in 2021 for $2.3B. Most comparable by SIRP-targeted mechanism and oncology overlap with Electra's ELA026 T-cell malignancy program.
• Sobi (Swedish Orphan Biovitrum): Sobi markets emapalumab (Gamifant), the only FDA-approved HLH therapy (primary HLH), generating $66.6M in Q3 2025 revenue (+98% YoY). It is the most directly comparable peer given overlapping disease area, hematology commercial footprint, and ultra-rare disease infrastructure.

Broad incumbents

• Alexion / AstraZeneca Rare Disease: Global rare disease commercial leader with a complement- and hematology-focused portfolio (e.g., Ultomiris, Soliris). Comparable on commercial-scale rare-disease hematology infrastructure and potential M&A analog for Electra.
• Gilead Sciences (magrolimab / CD47 program): Gilead developed magrolimab (anti-CD47) for MDS/AML and acquired Forty Seven. While mechanistically adjacent (CD47/SIRPα axis), it's a broader immunology/oncology incumbent rather than a focused sHLH/SIRP player and serves as a benchmark for the SIRP-targeting space.
• BioMarin Pharmaceutical: Ultra-rare disease commercial-stage biotech with multiple orphan franchises and hematology/R&D capability. Comparable as a benchmark for late-stage rare-disease clinical biotechs with single asset valuation drivers.
• Incyte Corporation: Mid-cap biotech with a deep myeloproliferative neoplasm and graft-versus-host-disease portfolio (Jakavi, ruxolitinib). Overlaps with Electra on hematology/immunology focus and is a frequent benchmark for rare hematology commercial infrastructure.

Others

• Star Therapeutics: Electra's parent company and inception engine. Star incubated Electra and runs sibling programs (e.g., Vega/VGA039). Relevant as a strategic/operational comparator reflecting shared scientific and corporate infrastructure.
• True North Therapeutics (acquired by Sanofi via Bioverativ): Direct predecessor company whose alumni founded and operate Electra; developed sutimlimab (Enjaymo), approved for cold agglutinin disease. Acquired by Bioverativ for $825M then by Sanofi. Closest cultural and operational analog for Electra's likely strategic trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/electra-tx

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Electra Therapeutics